Document is current
Any future updates will be listed below
-
Authors
Robertson, Neil A. https://orcid.org/0000-0002-9509-1157
Latorre-Crespo, Eric
Terradas-Terradas, Maria https://orcid.org/0000-0002-3823-8968
Lemos-Portela, Jorge
Purcell, Alison C. https://orcid.org/0000-0002-2911-9035
Livesey, Benjamin J. https://orcid.org/0000-0001-6866-1452
Hillary, Robert F. https://orcid.org/0000-0002-2595-552X
Murphy, Lee https://orcid.org/0000-0001-6467-7449
Fawkes, Angie
MacGillivray, Louise
Copland, Mhairi https://orcid.org/0000-0002-7655-016X
Marioni, Riccardo E.
Marsh, Joseph A. https://orcid.org/0000-0003-4132-0628
Harris, Sarah E. https://orcid.org/0000-0002-4941-5106
Cox, Simon R.
Deary, Ian J.
Schumacher, Linus J. https://orcid.org/0000-0003-0797-3406
Kirschner, Kristina https://orcid.org/0000-0001-7607-8670
Chandra, Tamir https://orcid.org/0000-0002-7935-317X
-
Funding
Funding for this research was provided by:
Univesity of Edinburgh Chancellors Fellowships
RCUK | Medical Research Council (MR/N013166/1, MC_UU_00009/2, MR/M01311/1, MR/K026992/1)
University of Edinburgh Chancellors Fellowship
Leukemia UK
- License Information
-
More Information
Article History
Received: 3 September 2021
Accepted: 27 May 2022
First Online: 4 July 2022
Competing interests
: K.K. received a reagent grant from ArcherDX/Invitae. L.M. consults for Illumina. M.C. has received research funding from Cyclacel and Incyte, is/has been an advisory board member for Novartis, Incyte, Pfizer and Jazz Pharmaceuticals and has received honoraria from Astellas, Novartis, Incyte, Pfizer and Jazz Pharmaceuticals. The remaining authors declare no competing interests.
